---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027107"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:08:15.046536+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics Q2 net loss $16.7M; on track for EB-101 BLA submission in Q3 2023

## Summary
- Net loss $16.7M ($0.92/share) vs $7.9M ($1.36/share) in Q2 2022; revenue $3.5M from license.
- Cash $37.1M at June 30; $25M July offering extends runway into Q4 2024.
- BLA submission for EB-101 in RDEB on track for Q3 2023; pre-BLA briefing submitted to FDA.
- Completed Process Performance Qualification runs for commercial production of EB-101.
- Additional Phase 3 VIITAL efficacy/safety data presented at ISID and SPD meetings.

## SEC filing metadata
- accession: 0001493152-23-027107
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/0001493152-23-027107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027107
- JSON: https://secwatch.observer/filing/0001493152-23-027107.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027107.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported second quarter of 2023 results: revenue $3.5 million, net income $16.7 million, EPS $0.92 loss per common share.
  - Period: second quarter of 2023
  - Revenue: $3.5 million
  - Net income: $16.7 million
  - EPS: $0.92 loss per common share
  - Result: reported results
  source text: direct offering in July 2023, are sufficient resources to fund operations into the fourth quarter of 2024. License and other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022. Research and development expenses for the three months ended June 30, 2023 were $8.5 million, compared to $6.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/0001493152-23-027107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.